Vitamin A deficiency (VAD) is associated with increased susceptibility to carcinogenesis in animal models and elevated risk for a number of human cancers. Here, we found that CYP26A1, the gene encoding a cytochrome P450 enzyme specifically involved in metabolic inactivation of retinoic acid (RA), the most active vitamin A derivative, is highly expressed in 42% (27/65) of primary breast cancers. We also showed that enhanced expression of CYP26A1 suppresses cellular responses to anoikis and consequently promotes anchorage-independent growth. This transformed phenotype was sufficient to markedly increase tumorigenic and metastatic potential. Suppression of CYP26A1 significantly reversed the CYP26A1-mediated oncogenic characteristics, suggesting a direct link between intracellular RA status and tumorigenicity. Our observations provide strong evidence for oncogenic and cell survival properties of CYP26A1 in carcinogenesis, and suggest mechanisms whereby VAD might promote cancer development.
Introduction
Vitamin A is important for health. The vitamin A metabolite, all-trans retinoic acid (atRA), has essential roles in the formation and maintenance of tissues, stemming from its potency as a regulator of cell proliferation, differentiation and apoptosis. Although essentially all cell types express nuclear RA receptors (RA nuclear receptors and retinoid-X-receptors) and can potentially respond to RA to positively or negatively regulate expression of RA target genes (Chambon, 1996) , cellular responsiveness is determined by the bioavailability of RA. This is regulated by the vitamin A nutritional status and the coordinated balance between RA biosynthesis and catabolism. RA-catabolizing cytochrome P450 enzymes (CYP26A1, B1 and C1) are specifically involved in the metabolic inactivation of RA, and thus limit RA bioavailability of the cell by restricting RA access to transcriptional machinery by converting RA to biologically inactive metabolites (White et al., 1997; Abu-Abed et al., 2001; Petkovich, 2001; Osanai and Petkovich, 2005) .
Early studies of retinal deficiency on animals have shown a plausible association between vitamin A deficiency (VAD) and carcinogenesis (Wolbach and Howe, 1925) ; however, the underlying mechanisms explaining how VAD might contribute to the high incidence of cancer and increased susceptibility to carcinogenic insult remain to be defined. Despite the fact that the CYP26 enzymes may have a similar but separate role in limiting the consequences of fluctuations in nutritional vitamin A, the possibility that pathological conditions such as cancer might involve aberrant expression of CYP26A1 has recently emerged from several studies. Accumulating evidence has shown that enhanced RA catabolic activity has been observed in various types of cancer and elevated CYP26A1 expression has been detected in a number of cancer cell types (Sonneveld et al., 1998; Van heusden et al., 1998; Shelton et al., 2006; Chang et al., 2008) . On the other hand, our previous study has shown that the cells expressing CYP26A1 gain significant resistance to apoptosis because of the state of reduced bioavailability caused by the metabolic inactivation of RA (Osanai and Petkovich, 2005) . Although the consequence of elevated CYP26A1 activity in tumor cells is not clear, clinical observations support the possibility that CYP26A1-mediated catabolism could be involved in abrogating the beneficial tumorsuppressive effects of endogenous RA and the optimal therapeutic efficacy of exogenous RA (Fenaux and Degos, 1997; Kizaki et al., 1997) . Conversely, numerous clinical studies have provided support for the use of RA in the treatment of malignancies and premalignant lesions, as well as for chemoprevention (Lotan, 1996; Altucci and Gronemeyer, 2001) . Although a relationship between cellular RA status and tumorigenesis is compelling, it remains to be clarified whether RA depletion through metabolic mechanism might promote tumor development. Here, we show that the CYP26A1-mediated catabolism of RA results in a state of functional VAD that can contribute to carcinogenic processes.
Results

Primary breast cancers overexpress CYP26A1
Several investigators have revealed that deregulated overexpression of CYP26A1 could be detected in a number of cancer cell types, including breast carcinomas (Sonneveld et al., 1998; Van heusden et al., 1998) . First, we investigated the expression of CYP26A1 in breast cancers with tissue microarray slides. We found only weak positive reactivity in ducts and lobules within normal breast tissues (Figure 1a ; Supplementary  Figure 1 ), whereas distinct strong cytoplasmic staining was observed in 23 of 50 (46%) breast carcinomas (Figures 1b-d ; Supplementary Table 1 ). In addition, metastatic carcinomas had significantly higher CYP26A1 expression, suggesting a potential role of CYP26A1 in tumor development.
Importantly, strong positive staining was also observed in 27 of 65 (42%) surgically resected breast cancer specimens (Supplementary Table 2 ). A KaplanMeier analysis of these cases suggested that high expression of CYP26A1 might be associated with decrease in both disease-free (P ¼ 0.011) and overall survival (P ¼ 0.026). However, no direct proof exists to support this observation mainly because of limited numbers of a well-characterized series of patients with breast cancer with a long-term follow-up. We did not observe any increase in gene copy number for the CYP26A1 locus by fluorescent in situ hybridization analyses (data not shown). Consistent with these observations, transcriptional complexity should be noted for understanding the regulatory mechanism of CYP26A1 overexpression during the carcinogenic scenario (Loudig et al., 2000 (Loudig et al., , 2005 .
Establishment of CYP26A1-overexpressing cells
To deplete cells of RA in vitro, we generated two independent CYP26A1 constitutively overexpressing pools of AC2M2 cells, a metastatic variant of the breast cancer cell line, designated AC2M2-CYP26#1 and -CYP26#2. Previous reports showed that certain cell lines such as MCF-7 show inducible endogenous CYP26A1 expression after atRA treatment (White et al., 1997) , but AC2M2 cells transfected with an empty vector did not express CYP26A1, with or without atRA pretreatment. In contrast, AC2M2-CYP26A1#1 and -CYP26A1#2 cells abundantly expressed CYP26A1 mRNA at similar levels ( Figure 2a ). CYP26A1#2 cells expressed a slightly higher CYP26A1 protein level but with significantly higher catabolic activity than CYP26A1#1, in both cases inhibitable by prior transfection of CYP26A1-specific small interfering RNA (siRNA; Figures 2b and c) . Altered gene expression profile provides oncogenic and cell survival properties in CYP26A1-expressing cells We next assayed the gene expression profiles of control cells and CYP26A1 transfectants using cancer pathwayspecific cDNA microarrays to examine the possibility that mRNA induced or suppressed by CYP26A1 expression was responsible for the tumor pathology ( Figure 3 ). Although ER-positive breast cancers generally have a better prognosis and are often responsive to anti-estrogen therapy, ER-negative breast cancers are more aggressive and unresponsive to anti-estrogens. Surprisingly, changes in patterns of gene expression were similar between ER-positive MCF-7 clones and the mixed populations of ER-negative AC2M2 transfectants ( Figure 3a ). CYP26A1 expression affects regulation of an extensive range of oncogenic pathways including oncogenes, tumor suppressor genes, and components of the apoptotic machinery, as well as death receptor family members (Figures 3b and c) .
Although apoptosis is linked with deregulated cell cycle events and impaired DNA damage repair systems (Evan and Vousden, 2001) , an underlying part of these abnormalities may be associated with the RA status in the cells based on the changes in gene expression associated with this mechanism such as p16 Ink4 and chk2. Signaling through the Akt and mitogen-activated protein kinase (MAPK) pathways may be also modulated by CYP26A1. CYP26A1 expression may affect not only the wide range of signaling pathways in the cell but also the tumor microenvironment and tumor cell-interstitial cell interactions, shown by the altered expression of cell adhesion molecules such as integrins. Further evidence includes the possible association of gene families involved in tumor cell invasion and metastasis such as uPA, and angiogenesis such as VEGF. These gene expression alterations suggest that many of the genes involved in cancer pathways are modulated to favor cell survival when CYP26A1 is overexpressed.
CYP26A1 overexpression provides increased resistance to anoikis Evasion of apoptosis is a hallmark of cancer and resistance to anoikis (apoptosis resulting from loss of cell-matrix interaction) may be a predominant contributor to neoplastic progression (Evan and Vousden, 2001; Gozani et al., 2002) . Our previous studies showed that various cell lines overexpressing CYP26A1 gain significant resistance to a number of apoptogenic stimuli (Osanai and Petkovich, 2005) . Consistent with the ability of CYP26A1 to suppress apoptosis, we verified that CYP26A1 overexpression provided the given cells with decreased susceptibility to a number of differently acting apoptogens, without cell-type specificity (Supplementary Figure 2 ). Therefore, we next examined the possibility whether CYP26A1 overexpression suppresses anoikis. As hypothesized, the apoptotic sensitizing effect of atRA increased the sensitivity of anoikis in control cells, whereas CYP26A1 transfectants showed significant resistance even in the presence of atRA over time ( Figure 4a ). This decreased apoptotic sensitivity of AC2M2-CYP26A1#2 cells was partially but significantly abrogated by CYP26A1-specific siRNA-mediated silencing (Figure 4b ), suggesting the catalytic activity of the enzyme to be important for its antiapoptotic effects. In addition, CYP26A1-expressing cells showed an accelerated cell growth rate relative to the AC2M2 controls. Although we observed that the basal levels of apoptosis were different between controls and CYP26A1 transfectants (Figures 4a and b) , there was evidence that normal fetal bovine serum (FBS) contained a physiological concentration of atRA, which Role of CYP26A1 in carcinogenesis M Osanai et al is known to be sufficient to switch on the RA-driven transcriptional machinery (Osanai and Petkovich, 2005) . This is also explained by the observation that the basal level of apoptosis was not changed in the event of CYP26A1 overexpression in medium supplemented with endogenous RA-depleted (for example charcoal-dextran treated) FBS (data not shown). Importantly, endogenous CYP26A1 expression also provided lower sensitivity to anoikis, allowing exclusion of the possibility that the forced expression of CYP26A1 resulted in possible unidentified artifacts (Figure 4c ). We next determined by immunoblotting the protein levels of cleaved caspase-3, a primary executioner of apoptosis. No activated caspase-3 was detected in any of the cells when grown on adhesive dishes, but it was produced by control cells when they were brought into suspension (Figure 4d ).
By contrast, cleaved caspase-3 production was dramatically suppressed by CYP26A1 transfection. These results indicate that CYP26A1 effectively suppresses the apoptotic sensitivity of the cells.
CYP26A1 is predominantly associated with MAPK signaling
To examine the signal transduction pathways involved in the CYP26A1-mediated apoptotic resistance, we used various specific kinase inhibitors. An MAPK inhibitor (PD98059) significantly restored sensitivity to anoikis, which was suppressed by CYP26A1, whereas other inhibitors such as a p38 MAPK inhibitor (SB203580) and a phosphoinositide-3-kinase (PI3K) inhibitor (LY294002) had significant but much less marked effects when compared with that by PD98059 (Figure 4e ). 
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Consistent with this, the protein level of pMAPK was increased in AC2M2-CYP26A1#2 cells; this upregulation was significantly abrogated by the treatment with CYP26A1-specific siRNA, suggesting that CYP26A1 is predominantly associated with the MAPK signaling pathway.
CYP26A1 overexpression enhances tumorigenic potency in vitro
We next evaluated the ability of tumor cells to grow under anchorage-independent growth conditions, a measure of cell transformation. Shifting the cells from adhesive to non-adhesive dishes resulted in massive cell death in control cells, whereas CYP26A1 expression effectively suppressed anoikis and contributed to the formation of large spheroid-like aggregates in suspension ( Figure 5a ). Similarly, although both of the control cells and CYP26A1 transfectants showed anchorageindependent growth in soft agar, CYP26A1-expressing cells grew as colonies more than sixfold in number, a property not observed in the AC2M2 controls ( Figure 5b ). In addition, CYP26A1 allowed anchorage-independent growth, forming significantly larger colonies relative to the parental control. In particular, AC2M2-CYP26A1#2 cells that exhibited higher RA catabolic activity than AC2M2-CYP26A1#1 Role of CYP26A1 in carcinogenesis M Osanai et al produced larger colonies (Figure 5c ). Transfection with CYP26A1-specific siRNA partially but significantly abrogated the CYP26A1-mediated increase of colonyforming capabilities, making it possible to link the expression of CYP26A1 with the observed phenotypes ( Figure 5b ). The partial effects of siRNA might primarily be caused by transient transfection, in which expression of the transfected gene decreases with cell division. If the partial effects of siRNA might be due to limitations of transient transfection, this might also affect other data shown in this study. Other breast carcinoma cell lines showed similar results, regardless of the presence of ER, so that the effect by CYP26A1 was not cell type specific (Figure 5d ). The data were also supported by the observation that the cells transfected with deletion mutants of CYP26A1 showed a positive correlation between colony-forming efficacy in soft agar and the catabolic activity of atRA (Supplementary Figure 3) . These observations suggest that the expression of CYP26A1 potentially contributes to the acceleration of anchorage-independent growth in association with the RA status regulated by metabolic processes in the cells.
CYP26A1 mediates enhanced tumorigenicity in vivo and contributes to cancer metastasis To address whether CYP26A1 enhances tumorigenicity, we next used orthotopic transplantation in mice. Expression of CYP26A1 in AC2M2 cells was sufficient to enhance in vivo tumorigenicity, causing a markedly accelerated rate of tumor formation in mammary fat pads relative to the controls (Figures 6a and b) . The cells comprising CYP26A1-expressing tumors showed highgrade malignant characteristics, including a lower apoptosis and a higher mitotic index, and enhanced infiltration into subcutaneous connective tissue with small necrotic foci, indicative of rapid tumorigenesis (Figures 6c and d) . These data support the possibility that the acquisition of CYP26A1-mediated enhanced tumorigenicity is associated with RA metabolism in the cells. The histopathological examination of CYP26A1-overexpressing AC2M2 cell-derived tumors also revealed more vascular components than those derived from controls ( Figure 6d ). Interestingly, CYP26A1-expressing AC2M2 cells showed significantly higher VEGF expression and this elevated expression could be partially downregulated by treatment with CYP26A1-specific siRNA (Figure 6e ). This observation suggests the possible mechanistic link between the CYP26A1-mediated degradation of RA and angiogenic activity in tumor tissue, which is in good agreement with the evidence that RA is known to have an angiogenesis-inhibiting activity. As pathological angiogenesis is an important contributing factor in tumor formation and progression, it is plausible that enhancement of tumor growth by CYP26A1 could be both the result of effects on the tumor cells as well as on the tumor microenvironment. However, the interaction between tumor microenvironment and genetic mechanisms influencing tumor angiogenesis and growth is complex and is only now Role of CYP26A1 in carcinogenesis M Osanai et al beginning to be elucidated. Consistent with the ability of CYP26A1 to suppress anoikis, CYP26A1-transfected AC2M2 cells showed an enhanced potential to metastasize to the lung and metastases contained fewer apoptotic cells (Figure 6f ). These results indicate that CYP26A1-mediated acquired phenotypes such as enhanced tumorigenicity and metastatic behaviors are likely associated with RA bioavailability in cells.
Discussion
Our observations unveil a mechanistic link between RA catabolism and enhanced tumorigenicity, implicating CYP26A1 as a possible candidate oncogene. This is in line with earlier studies suggesting that VAD is associated with carcinogenesis (Wolbach and Howe, 1925) , and upregulation of CYP26A1 has recently been shown in a number of cancer cell types (Sonneveld et al., 1998; Van heusden et al., 1998; Shelton et al., 2006; Chang et al., 2008) . If increased RA metabolism is solely responsible for the apoptogen desensitizing effect, our results would imply that in a state of RA deficiency, cells may be less susceptible to apoptosis following the acquisition of DNA damage. As a corollary, individuals suffering from VAD might be expected to accumulate DNA damage with higher frequency. This may provide a plausible explanation for the increased incidence and higher risk of cancer formation and development observed in individuals with VAD. Epidemiological studies have not only shown that an increased incidence of lung cancer has been observed in individuals with VAD, but have also pointed to an association between VAD and cancers arising in the uterine cervix, oral cavity and oropharynx (French et al., 2000) . Similarly, ultraviolet irradiation induces a functional VAD state in skin that may contribute to skin carcinogenesis, suggesting an association between VAD and a high risk of some types of cancer (Wang et al., 1999) . CYP26A1 confers unique cell-survival properties on cells, modulating a wide variety of genes to favor cell survival, which results in a selective growth advantage to the cells. We have shown that the intracellular RA status regulated by the expression of CYP26A1 has a central role in determining the cellular sensitivity to apoptosis, and that a state of reduced RA bioavailability suppresses cellular response to proapoptotic or several different inducers of apoptosis (Osanai and Petkovich, 2005) . Consistent with the protective role played by CYP26A1 against a broad range of apoptogens, CYP26A1 upregulation effectively affects the gene expression signature already present in tumor cells to potentially generate a wide variety of specific and potent pro-survival signals that render cells resistant to anoikis. In view of the multiple signaling pathways, overexpression of CYP26A1 has been shown to lead to induction of oncogenes such as c-Myc and epidermal growth factor receptor, repression of tumor suppressor genes, and deregulation of cell cycle and DNA repair genes, suggesting a gene expression pattern favoring cell survival with antiapoptosis signals (Chang et al., 2008) . Therefore, it is acceptable to believe that alterations of several signaling pathways attributable to CYP26A1 expression contribute to inactivation of and/or escape from multiple cellular transformation events (oncogenic 'hits'), eventually enhancing tumor formation and progression. CYP26A1 activation also results in the acquisition of metastatic potency, which provides a possible explanation for the aggressive nature of human breast carcinomas that overexpress CYP26A1. There is still a possibility that CYP26A1 overexpression causes intracellular RA depletion that drives the cells into a highly oncogenic state with induction of other known oncogenes.
We have shown that the suppression of CYP26A1 significantly reverses CYP26A1-mediated oncogenic characteristics, suggesting a direct link between intracellular RA status and tumorigenicity. Importantly, knockdown experiments were not possible because of the low basal CYP26A1 transcript levels in commercially available breast carcinoma cell lines, though primary breast carcinomas should have high CYP26A1 expression. As our preliminary experiment was confirmed in MCF-7 cells for which we have well-established profiles of CYP26A1 expression and inducibility, we used MCF-7 cells treated with atRA to show that suppression of endogenous CYP26A1 provided increased sensitivity to apoptosis. There remains a possibility that forced expression of CYP26A1 may have some additional interesting but as yet uncharacterized effects on the cells. To exclude that forced expression of CYP26A1 can lead to non-specific effects on the cells, it is necessary to use conditional knockout approaches to completely assess CYP26A1 function, as total knockout of CYP26A1 shows embryonic lethality (Abu-Abed et al., 2001). Interestingly, the abrogation of the functional effects of CYP26A1 overexpression by specific inhibitors of CYP26A1, which are not yet commercially available, would provide a detailed molecular mechanism explaining oncogenic and cell survival properties of CYP26A1.
The CYP26A1 enzyme primarily protects cells and tissues from exposure to RA, having important roles in finely regulating RA distribution in tissues during embryogenesis. Given the pleiotropic activity of RA, it is not surprising that CYP26A1 expression can affect a vast array of physiological pathways in regulating various independent signaling molecules associated with tumorigenic events. Indeed, this is strongly suggested by CYP26A1 knockout animals, which exhibit severe caudal regression syndrome and embryonic lethality (Abu-Abed et al., 2001) . Conversely, recapitulation of CYP26A1 expression in cancer cells would provide a selective growth advantage to these cells and thus evade normal apoptotic mechanisms. Therefore, strategies that decrease activity of CYP26A1 may be an important means of increasing the sensitivity of cancer cells to proapoptotic therapies. We believe that specific drug-mediated inactivation of CYP26A1 may have a notable impact on the malignant potential of human tumors with overexpressed CYP26A1, and that these results show the potential feasibility of CYP26A1-inhibitory cancer therapies.
Materials and methods
Patient samples
We used archival formalin-fixed, paraffin-embedded tissue specimens prepared from surgically resected breast carcinomas. Informed consent was obtained from patients for pathological assessment of their surgical specimens. Histological type of breast cancer was classified by the WHO guidelines (Tavassoli and Devilee, 2003) , and pathological tumor stage was defined according to the TNM classification of malignant tumors of the International Union Against Cancer (Sobin and Wittekind, 2002) . As patients with no further follow-up information were excluded from the list in this study, all patients were followed up for a minimum of 6 years.
Immunohistochemistry After deparaffinization and antigen retrieval, 4 mm tissue sections and tissue microarray slides (Super Bio Chips, Seoul, Korea) were incubated overnight at 4 1C with primary antibodies against CYP26A1 (Santa Cruz Biotechnologies, Santa Cruz, CA, USA), Ki67 (Dako, Glostrup, Denmark) or CD34 (Dako). The sections were then reacted with EnVision (Dako) for 30 min at room temperature. We routinely used positive and negative controls, and confirmed the results in independent duplicate analyses. Positive staining was graded as percentage of tumor cells stained: 3 þ (strong), staining in >50% of the cells; 2 þ (moderate), staining in >25% of the cells, 1 þ (low), staining in >5% of the cells, 0 (negative), no or faint staining in o5% of the cells. We considered CYP26A1 expression to be strong with staining grades 2 þ or 3 þ , and considered a test result of 0 and 1 þ as negative.
Cell line
All cell lines were maintained in DMEM (Life Technologies, Grand Island, NY, USA) supplemented with 10% FBS (Life Technologies). AC2M2 cell line is a metastatic variant of SP1 breast carcinoma cells, isolated from a mammary intraductal adenocarcinoma, which arose spontaneously in an 18-monthold CBA/J female retired breeder (Elliott et al., 1988) . AC2M2 and MDA-MB-231 cells are ER negative, and MCF-7, ZR75-1 and T-47D cells are ER-positive breast carcinoma lines.
Construction of expression vectors and transfection
Full-length CYP26A1 cDNA (GeneBank accession number, NM_000783) was amplified by reverse transcription (RT)-polymerase chain reaction (PCR) from total RNA extracted from MCF-7 cells pretreated with atRA (White et al., 1997) . After subcloning by a TA cloning (Invitrogen, Carlsbad, CA, USA), the cDNA fragment of CYP26A1 was ligated into the pcDNA3.1(À) expression vector (Clontech, Palo Alto, CA, USA), yielding pcDNA3.1(À)-CYP26A1. Likewise, we also made a number of deletion mutants (Supplementary Figure 3) .
We transfected cells with 5 mg of each plasmid using the FuGene6 transfection reagent (Roche, Basel, Switzerland) to generate stable transfectants. Selection of clones was carried out in AC2M2 cells in the presence of 0.8 mg/ml G418 (Sigma, St Louis, MO, USA). After 15 days of selection, the drugresistant clones were picked up and screened for their RA catabolic activity. Our preliminary experiments showed that observed phenotypes of the cells in the event of CYP26A1 overexpression were similar but not exactly the same with at least three different independent clones. Therefore, cells were equally mixed to establish stably transfected cell lines to avoid possible clonal variation and to exclude the possibility that cloning procedures selected for a more tumorigenic phenotype. We transfected an empty vector as a control.
Two concentrations of siRNA targeted to CYP26A1 (25 or 50 nM; Santa Cruz) were also transfected into cells using the FuGENE6 reagent 48 h before the treatment, with or without another reagent such as atRA for 24 h. Negative control siRNA was used as control to show that the transfection itself had no specific effects on gene expression.
Anoikis induction AC2M2 cells were prevented from adhering to the plastic of cell culture dishes to induce anoikis (Osanai et al., 2006) . In some experiments, atRA (10-2.5 mM, 0.1 mM as a default concentration; Sigma), which is an apoptotic sensitizer (Osanai and Petkovich, 2005) , an MAPK inhibitor (PD98059, 50 mM, Sigma), p38 MAPK inhibitor (SB203580, 20 mM, Sigma) or PI3K inhibitor (LY294002, 20 mM, Sigma) were added.
MCF-7 cells were also subjected to this assay. Our preliminary experiment confirmed that MCF-7 cells constitutively expressed CYP26A1 in medium supplemented with 10% FBS, and that atRA could strongly induce CYP26A1 levels in MCF-7 cells. Cells were transfected with CYP26A1-specific siRNA (50 nM) 48 h before apoptotic stimulation, followed by the induction of anoikis in serum-starved fresh medium in the presence of 1 mM atRA.
Soft agar assay
Soft agar assays were carried out in 6 cm dishes to assess colony formation in three dimensions (Osanai et al., 2006) . Cells were incubated during the time until either cells of control or their transfectant grew more than B200 mm in diameter. Colonies developing on cell culture dishes in soft agar suspension were scored using phase contrast microscopy by counting colony numbers under low magnification ( Â 100) in 10 separate arbitrary fields in each plate. Cell clusters more than approximately 50 mm in diameter were defined as positive results in the soft agar assay. In the quantitative analysis, the number of colonies formed from control cells was defined as 100%.
Terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) assay Multicellular spheroids and tumor tissues developing in mice were fixed with 70% methanol and embedded in 1% agar or paraffin. TUNEL assays were performed to visualize the apoptotic cells using an In Situ Cell Death Detection Kit (Roche). We also ran the staining procedure without TdT as a negative control. The cells of interest were scored under a light microscope by counting the number of cells under low magnification ( Â 100) in 10 randomly selected fields in each section.
Western blot analysis
Whole cell lysates, each with 20 mg of denatured proteins, were run on 12-15% SDS-polyacrylamide gels and electroblotted onto nitrocellulose filters. These were immunoblotted with antibodies against CYP26A1 (Santa Cruz), pMAPK (Cell Signaling, Beverly, MA, USA), ERK1/2 (Promega, Madison, WI, USA), and b-actin (Santa Cruz) proteins. The filters were then reacted with corresponding peroxidase-labeled secondary antibodies, and immunoreactions were visualized using an enhanced chemiluminescence system (GE Healthcare, Buckingham, UK). For densitometric analyses, signals were quantitated using Scion Image 1.62 (Scion Corporation, Frederick, MD, USA), and the level in control cells was defined as 100%. To show the signal intensity of pMAPK/ ERK1/2, signals of pMAPK (p44) were normalized to the expression of ERK1/2 (p44) in each sample.
Semiquantitative RT-PCR and Southern blot analysis Total RNA (1 mg) extracted using TRIzol (Invitrogen) was reverse transcribed using M-MuLV reverse transcriptase (Invitrogen). For analysis of gene expression, the gene of interest was amplified from dilutions of cDNA for up to 40 cycles, and we examined various cycling parameters for each PCR experiment to define optimal conditions for linearity to allow semiquantitative analysis of signal intensity. Electrophoresed DNA from the agarose gel was transferred to a Hybond N þ nylon membrane overnight (GE Healthcare). Full-length cDNA of each gene was used as a probe labeled with [
32 P]dCTP to a specific activity of B1 Â 10 9 cpm/mg using a random priming-based cDNA labeling kit (Nippon Gene, Tokyo, Japan). To provide a qualitative control, PCR reactions were also performed with primers coding for glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Triplicate independent PCR reactions were carried out to confirm reproducibility of expression quantification.
Tumor growth in vivo
We injected cells of AC2M2 and its transfectant (10 ml volume of cells/mouse) into mammary fat pads of 6-or 7-week-old female mice (CBA/J; Charles River Japan, Yokohama, Japan; Osanai et al., 2006) . Animals were killed as a function of time when skin ulceration of the primary tumor occurred. We examined the primary tumor and all organs, including lungs, macroscopically for evaluation of tumor and metastases, followed by histological evaluation for pulmonary micrometastases. Tumor angiogenesis was evaluated in terms of the CD34-positive microvasculature in tumors developed in mice. The maintenance and handling of animals were carried out using protocols approved by the Animal Care Committee of the University.
cDNA array analysis Cancer Pathway Finder Gene Arrays by GEArray (SuperArray, Bethesda, MD, USA) were used to examine the possibility that mRNAs induced or suppressed by CYP26A1 expression were responsible for changes in the tumor pathology (Osanai and Petkovich, 2005; Osanai et al., 2006) . To consider possible variations in RNA quantification between samples, the signal intensity of a given gene was normalized to that derived from GAPDH on the same membrane and expressed in arbitrary units. Gene-expression changes caused by CYP26A1 expression were then normalized to the values in control cells.
Statistical analysis
Statistical analysis was performed using StatView 5.0 software. Unless otherwise specified, all data represent the mean±s.d. of at least three independent experiments, each in triplicate specimens, and we evaluated experimental results using the paired t-test. Overall survival and disease-free periods were examined by the Kaplan-Meier method with a log-rank test to assess their significance. Association between CYP26A1 immunoreactivity and different clinicopathological parameters in breast carcinoma was studied using the w 2 test. A P-value of o0.05 was considered significant.
